FORMULATIONS FOR DERMAL DELIVERY OF POLYMER CONJUGATES OF INDOLOCARBAZOLE COMPOUNDS WITH REDUCED EXPOSURE

Topical formulations to treat skin conditions, such as atopic dermatitis, psoriasis, pruritus, are provided in which a polymer conjugate of an indolocarbazole exhibits reduced systemic exposure. An example formulation includes the TrkA/JAK/MAP kinase antagonist, SNA-125, in a cream formulation. L�...

Full description

Saved in:
Bibliographic Details
Main Authors KHEIR, Majed, MAINERO, Valentina, TRAVERSA, Silvio, WONG-MOON, Kirby
Format Patent
LanguageEnglish
French
Published 25.07.2019
Subjects
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
Online AccessGet full text

Cover

More Information
Summary:Topical formulations to treat skin conditions, such as atopic dermatitis, psoriasis, pruritus, are provided in which a polymer conjugate of an indolocarbazole exhibits reduced systemic exposure. An example formulation includes the TrkA/JAK/MAP kinase antagonist, SNA-125, in a cream formulation. L'invention concerne des formulations topiques servant à traiter des affections cutanées, telles que la dermatite atopique, le psoriasis, le prurit dans lesquelles un conjugué polymère d'un indolocarbazole présente une exposition systémique réduite. Une formulation donnée à titre d'exemple comprend l'antagoniste de la kinase TrkA/JAK/MAP, du SNA-125, dans une formulation de crème.
Bibliography:Application Number: WO2019US14241